pubmed.ncbi.nlm.nih.gov

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment - PubMed

️Thu Jan 01 2015

Review

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment

Thomas P Monath et al. Vaccine. 2015.

Abstract

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety of live, recombinant viral vaccines incorporating genes from heterologous viruses inserted into the backbone of another virus (so-called "chimeric virus vaccines"). Many viral vector vaccines are in advanced clinical trials. The first such vaccine to be approved for marketing (to date in Australia, Thailand, Malaysia, and the Philippines) is a vaccine against the flavivirus, Japanese encephalitis (JE), which employs a licensed vaccine (yellow fever 17D) as a vector. In this vaccine, two envelope proteins (prM-E) of YF 17D virus were exchanged for the corresponding genes of JE virus, with additional attenuating mutations incorporated into the JE gene inserts. Similar vaccines have been constructed by inserting prM-E genes of dengue and West Nile into YF 17D virus and are in late stage clinical studies. The dengue vaccine is, however, more complex in that it requires a mixture of four live vectors each expressing one of the four dengue serotypes. This vaccine has been evaluated in multiple clinical trials. No significant safety concerns have been found. The Phase 3 trials met their endpoints in terms of overall reduction of confirmed dengue fever, and, most importantly a significant reduction in severe dengue and hospitalization due to dengue. However, based on results that have been published so far, efficacy in preventing serotype 2 infection is less than that for the other three serotypes. In the development of these chimeric vaccines, an important series of comparative studies of safety and efficacy were made using the parental YF 17D vaccine virus as a benchmark. In this paper, we use a standardized template describing the key characteristics of the novel flavivirus vaccine vectors, in comparison to the parental YF 17D vaccine. The template facilitates scientific discourse among key stakeholders by increasing the transparency and comparability of information. The Brighton Collaboration V3SWG template may also be useful as a guide to the evaluation of other recombinant viral vector vaccines.

Keywords: Brighton Collaboration; Risk/benefit assessment; Vaccine safety; Vaccines; Viral vector; Yellow fever vaccine.

PubMed Disclaimer

Cited by

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Condit RC, Kim D, Robertson JS, Excler JL, Gurwith M, Monath TP, Pavlakis G, Fast PE, Smith J, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO) Working Group. Electronic address: bc-coordinator@taskforce.org. Condit RC, et al. Vaccine. 2020 Nov 17;38(49):7708-7715. doi: 10.1016/j.vaccine.2020.08.009. Epub 2020 Sep 6. Vaccine. 2020. PMID: 32907759 Free PMC article. Review.
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.
Condit RC, Williamson AL, Sheets R, Seligman SJ, Monath TP, Excler JL, Gurwith M, Bok K, Robertson JS, Kim D, Michael Hendry R, Singh V, Mac LM, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Condit RC, et al. Vaccine. 2016 Dec 12;34(51):6610-6616. doi: 10.1016/j.vaccine.2016.04.060. Epub 2016 Jun 23. Vaccine. 2016. PMID: 27346303 Free PMC article. Review.
A Single Amino Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian Hosts.
de Wispelaere M, Khou C, Frenkiel MP, Desprès P, Pardigon N. de Wispelaere M, et al. J Virol. 2015 Dec 9;90(5):2676-89. doi: 10.1128/JVI.01176-15. J Virol. 2015. PMID: 26656690 Free PMC article.
Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.
Kongsgaard M, Bassi MR, Rasmussen M, Skjødt K, Thybo S, Gabriel M, Hansen MB, Christensen JP, Thomsen AR, Buus S, Stryhn A. Kongsgaard M, et al. Sci Rep. 2017 Apr 6;7(1):662. doi: 10.1038/s41598-017-00798-1. Sci Rep. 2017. PMID: 28386132 Free PMC article.
Growth, Pathogenesis, and Serological Characteristics of the Japanese Encephalitis Virus Genotype IV Recent Strain 19CxBa-83-Cv.
Tajima S, Maeki T, Nakayama E, Faizah AN, Kobayashi D, Isawa H, Maekawa Y, Bendryman SS, Mulyatno KC, Rohmah EA, Mori Y, Sawabe K, Ebihara H, Lim CK. Tajima S, et al. Viruses. 2023 Jan 14;15(1):239. doi: 10.3390/v15010239. Viruses. 2023. PMID: 36680278 Free PMC article.

References

1. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines. 2007;6(2):255–66. - PubMed
1. Excler JL, Parks CL, Ackland J, Rees H, Gust ID, Koff WC. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals. 2010;38(4):511–21. - PubMed
1. Limbach KJ, Richie TL. Viral vectors in malaria vaccine development. Parasite Immunol. 2009;31(9):501–19. - PubMed
1. Xing Z, Lichty BD. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 2006;86(3–4):211–7. - PubMed
1. Naim HY. Applications and challenges of multivalent recombinant vaccines. Hum Vaccin Immunother. 2012;9(3) - PMC - PubMed

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment - PubMed